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Inflammatory bowel disease (IBD) is a chronic and heterogeneous intestinal
inflammatory disorder. The medical management of IBD aims for long-lasting
disease remission to prevent complications and disease progression. Early
introduction of immunosuppression forms the mainstay of medical IBD
management. Large inter-individual variability in drug responses, in terms of
both efficacy and toxicity, leads to high rates of therapeutic failure in the
management of IBD. Better patient stratification is needed to maximize patient
benefit and minimize the harm caused by adverse events. Pre-treatment
pharmacogenetic testing has the potential to optimize drug selection and dose,
and to minimize harm caused by adverse drug reactions. In addition, optimizing
the use of cheap conventional drugs, and avoiding expensive ineffective drugs,
will lead to a significant reduction in costs. Genetic variation in both TPMT and
NUDT15, genes involved in thiopurine metabolism, is associated to an increased
risk of thiopurine-induced myelosuppression. Moreover, specific HLA
haplotypes confer risk to thiopurine-induced pancreatitis and to immunogenicity
to tumor necrosis factor-antagonists, respectively. Falling costs and increased
availability of genetic tests allow for the incorporation of pre-treatment genetic
tests into clinical IBD management guidelines. In this paper, we review clinically
useful pharmacogenetic associations for individualized treatment of patients with
IBD and discuss the path from identification of a predictive pharmacogenetic
marker to implementation into IBD clinical care.
Key words: Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis;
Pharmacogenetics; Personalized medicine
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Core tip: In recent years, strong pharmacogenetic associations for drugs used in the
management of inflammatory bowel disease (IBD) have been identified. However, the
implementation of pre-treatment pharmacogenetic testing into clinical guidelines has
been challenging. Particular groups of patients are needlessly exposed to (expensive)
drugs that are either ineffective or harmful. Pre-treatment screening for TPMT and
NUDT15 genetic variation should be incorporated into clinical IBD management
guidelines. Therapeutic recommendations based on HLA genetic variants, conferring risk
for thiopurine-induced pancreatitis and immunogenicity to tumor necrosis factor-
antagonists, respectively, should be further evaluated.
Citation: Voskuil MD, Bangma A, Weersma RK, Festen EAM. Predicting (side) effects for
patients with inflammatory bowel disease: The promise of pharmacogenetics. World J




Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is
a  chronic  inflammatory  disorder  of  the  gastrointestinal  tract.  The  therapeutic
armamentarium for IBD has rapidly expanded over the last two decades. Beyond
conventional therapies such as amino-salicylates, corticosteroids and thiopurines, the
development of  biological  therapies  has revolutionized the management of  IBD.
Although all of these therapies are effective, it is well known that the inter-individual
variability in therapy response is high with respect to both efficacy and toxicity. In
consequence, particular groups of patients are needlessly exposed to (expensive)
drugs that are either ineffective or harmful. This in turn causes a therapeutic delay
and is associated with increased morbidity and costs. Ultimately, therapeutic failure
may necessitate surgical treatment[1].
Personalized management in patients with IBD
To optimize patient outcomes and better utilize resources, it is crucial to be able to
appropriately select the correct initial therapy for each patient; that means we need to
determine the predictive factors of beneficial response without adverse events to
therapy. In fact, many physicians have been practicing personalized medicine with
their IBD patients for many years. It has been demonstrated, for example, that young
age, isolated colonic Crohn’s disease and elevated C-reactive protein levels at the
initiation of therapy are variables that favor a short-term response to infliximab[2,3].
Conversely,  smokers are less likely to respond than nonsmokers,  and those with
disease duration longer than 2 years are less likely to respond than those with a
shorter disease duration[4,5].  These clinical  factors,  however,  explain only a small
proportion of inter-individual variability in therapy response.
Pharmacogenetics
Genetic variation can affect individual responses to drugs in terms of both therapeutic
effects and adverse effects. In fact, pre-treatment genetic testing has already been
implemented  in  clinical  practice  outside  the  management  of  IBD.  In  metastatic
colorectal cancer patients, for example, pre-treatment screening for mutations in the
KRAS gene is recommended to predict the efficacy of anti-EGFR-targeted drugs such
as cetuximab[6].  Likewise, the human leukocyte antigen (HLA) class I allele HLA-
B*57:01 has been shown to be a major determinant of hypersensitivity to abacavir, a
drug used in the management of HIV. In Europe, the United States and Australia,
HLA-B*57:01 testing is now mandatory before prescribing abacavir[7].
PHARMACOGENETICS IN THE MANAGEMENT OF IBD
Within the context of IBD, implementation of pharmacogenetic (PGx) testing has the
potential to maximize patient benefit  by optimizing drug selection and dose and
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minimize harm caused by adverse events,  as several PGx associations have been
identified for drugs used in the management of IBD. This will lead to a significant
reduction in costs by several means. First of all, the use of relatively safe and cheap
conventional therapies can be optimized. Secondly, the prescription of expensive,
potentially ineffective or harmful drugs can be avoided. Finally, achieving optimal
dosing as early as possible will prevent morbidity during a dose-finding period.
In this opinion article,  we focus on robust PGx associations identified in well-
characterized  cohorts  of  patients  treated  for  IBD.  Unfortunately,  many  PGx
associations  proposed in  small  retrospective  candidate-gene studies  have failed
replication in independent cohorts[8]. Therefore, we will only consider genome-wide
significant associations that have been replicated in independent cohorts (Table 1).
Next,  we will  discuss challenges and future perspectives associated with the im-
plementation of PGx testing in clinical care of IBD.
Aminosalicylates
5-Aminosalicylates  (5-ASA),  such  as  mesalazine  and  olsalazine,  are  the  most
frequently prescribed class of drugs to induce and maintain remission in patients with
mild to moderately active ulcerative colitis[9].  5-ASA treatment is considered safe,
cheap and effective treatment to achieve long-term sustained steroid-free remission in
patients  with  mild  to  moderately  active  ulcerative  colitis.  Common side  effects
associated  with  5-ASA  include  flatulence,  abdominal  pain,  nausea,  diarrhea,
headache, dyspepsia and nasopharyngitis, which may occur in up to 10% of patients
using these drugs[9]. Rare adverse events include, among others, pancreatitis (1%) and
nephrotoxicity (approximately 0.2%). While 5-ASA induced nephrotoxicity is rare,
70%  of  these  patients  will  develop  irreversible  renal  injury  and  10%  require
permanent renal replacement therapy[10]. A recent genome-wide association study
identified HLA-DRB1*03:01  as a determinant of 5-ASA-induced nephrotoxicity[10].
Carriership of the risk allele is associated with a 3-fold increased risk of renal injury
after 5-ASA administration. However, the high frequency of this risk allele and the
low frequency  of  the  adverse  event  limits  its  clinical  utility,  and  it  is  therefore
currently not recommended to consider it in guiding treatment choice or monitoring
intervals.
Thiopurines
Thiopurines, consisting of azathioprine and its analogues 6-mercaptopurine and 6-
thioguanine, are the most commonly prescribed immunosuppressive agents used to
maintain  corticosteroid-free  remission  and  prevent  postoperative  recurrence  in
patients with IBD[11].  Although thiopurines are an effective and cheap therapeutic
option  for  maintenance  of  remission,  its  use  is  limited  by  commonly  occurring
adverse events. It has been estimated that 17% of European patients with IBD using
thiopurines develop adverse events that necessitate drug withdrawal[12]. Thiopurine
adverse events can be divided into dose-independent events, like pancreatitis and flu-
like  illness,  and  dose-dependent  events,  such  as  myelosuppression  and
hepatotoxicity. Although the standard doses of thiopurines in Asian countries are
lower than in Europe, the incidence of dose-dependent adverse events is much higher
in Asian populations than in Europeans[13,14]. Genetic polymorphisms, both in the HLA
region and in genes encoding enzymes involved in thiopurine metabolism, have been
identified as important determinants of adverse events. Large international initiatives
to identify genetic variants associated to the other common thiopurine adverse events,
such as flu-like illness and hepatotoxicity, are currently ongoing (e.g., the UK IBD
PRED4 and Helmsley IBD Exome studies)[15,16].
Thiopurine-induced myelosuppression
Thiopurine-induced myelosuppression (TIM) occurs in 4% of European individuals
and in up to 15% of individuals of Asian descent[12,14]. TIM usually occurs within a few
weeks of starting the drug but can happen at any time during the treatment course.
Most patients are asymptomatic, but serious opportunistic infection may occur and
there  is  an  estimated  mortality  of  1%[17].  There  is  substantial  evidence  linking
thiopurine S-methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15) enzyme
activity to TIM[18,19]. TPMT is a well-known enzyme that inactivates azathioprine and
6-mercaptopurine  through  methylation,  leaving  less  parent  drug  available  for
eventual anabolism to cytotoxic thioguanine metabolites.  Genetic variants in the
TPMT gene may lead to reduced or absent TPMT enzyme activity levels, which in
turn leads to high levels of cytotoxic thioguanine metabolites[20]. NUDT15 catalyzes
the  conversion  of  cytotoxic  thioguanine  metabolites  to  non-toxic  thioguanine
metabolites. Genetic variants in the NUDT15 gene lead to deficient NUDT15 enzyme
activity  levels,  which also  results  in  excessive  levels  of  cytotoxic  thioguanine[21].
Cytotoxic thioguanine metabolites contribute to the therapeutic effects of thiopurines
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Table 1  Pharmacogenetic associations in inflammatory bowel disease
Class of drugs Response Gene Clinical utility
5-Aminosalicylates1 Nephrotoxicity HLA-DRB1 No (low incidence, high allele frequency)
Thiopurines Myelosuppression TPMT NUDT15 Yes
Alopecia NUDT15 Yes
Pancreatitis HLA-DQA1-HLA-DRB1 Yes
TNF-antagonists Immunogenicity HLA-DQA1 Yes
1No attempt has been made to replicate this association in an independent cohort because of the scarcity of cases. Gene refers to the genes within genetic
variants that have been associated to specific drug responses. HLA: Human leukocyte antigen; TPMT: Thiopurine S-methyltransferase; NUDT15: Nudix
hydrolase 15.
but may lead to myelosuppression.
TPMT and NUDT15 act independently, and the likelihood of an individual having
deficient enzyme activities depends upon allele frequencies within the population.
Approximately 10% of individuals of European descent carry TPMT genetic variants.
Three TPMT genetic variants account for 90% of the TPMT deficiency in Europeans,
which together explain 25% of TIM[22,23]. In contrast, only 3% of Asians carry TPMT
genetic variants despite a higher incidence of TIM in Asians populations[14,24]. This
difference is largely explained by common genetic variation in NUDT15  in Asian
populations, which has been identified as a strong genetic determinant of TIM[25]. The
most common NUDT15 genetic variant, R139C, is present in approximately 10% of
individuals  of  Asian  descent[25].  More  recent  studies  have  identified  additional
NUDT15  genetic  variants  predictive for  TIM that  are also present  outside Asian
populations[26,27]. Although rare, these variants are associated with very large effect
sizes.  For example, a recently identified rare NUDT15  genetic variant,  present in
approximately 2% of individuals of European descent, is associated with a 38-fold
increased risk of TIM[27].
Patients with loss-of-function TPMT and NUDT15 genetic variants are at excessive
risk of TIM if they receive standard thiopurine dosing. Genetic variation within TPMT
or NUDT15 is defined by so-called star (*) alleles. Each star allele is defined by the
genotype at one or more loci within the gene, and these star alleles are used for the
annotation of  enzyme activity levels  of  TPMT and NUDT15,  respectively.  These
annotations can then be used for dosing recommendations based on pre-treatment
genotyping. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has
recently published detailed dosing recommendations based on TPMT and NUDT15
genotypes[28].  In short, reduced starting doses (30%-80% of target dose) should be
considered for TPMT or NUDT15 intermediate metabolizers,  while substantially
reduced doses (10% of target dose) or the use of an alternative agent should be used
for TPMT or NUDT15 poor metabolizers[28].
Thiopurine-induced pancreatitis
Thiopurine-induced pancreatitis (TIP) complicates thiopurine therapy in about 4% of
patients exposed[12]. TIP usually occurs within the first few weeks after initiation of
therapy. The pathogenesis of this potentially life-threatening, idiosyncratic adverse
event remains poorly understood. Genetic variants in HLA-DQA1-HLA-DRB1 have
recently been identified as strong genetic determinants of TIP in European patients
with  IBD[29,30].  Carriership  of  a  HLA-DQA1*02:01-HLA-DRB1*07:01  haplotype  is
associated with a 2.5-fold increased risk of TIP[29]. Given the risk allele frequency of
27% in European populations, homozygous patients would be subject to a risk of
approximately 17% of developing TIP[29]. Development of TIP is independent of the
thiopurine dose administered. To avoid administration of thiopurines to patients with
IBD who are homozygous at the HLA-DQA1-HLA-DRB1 haplotype, clinical utility
estimates indicate that 76 patients need to be genotyped to prevent one case of TIP[29].
Although these data show the potential  of  pre-treatment HLA-DQA1-HLA-DRB1
genotyping, it has not yet been incorporated in clinical treatment protocols.
Thiopurine-induced alopecia
Thiopurine-induced alopecia (TIA) is a well-recognized, dose-dependent, adverse
event in Asian populations,  with an incidence around 1.5%[14,31].  In contrast,  this
adverse  event  is  rare  in  individuals  of  European ancestry[12].  Although not  life-
threatening, severe alopecia may cause cosmetic problems requiring a long recovery.
Small case-control studies reported co-occurrence of severe TIA with severe TIM in
patients homozygous for NUDT15  R139C[32,33].  A recent genome-wide association
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study in Japanese patients with IBD has shown that carrying the NUDT15 R139C risk
allele is associated with a 10-fold increased risk of TIA[13]. Avoidance of thiopurines in
patients homozygous for NUDT15 R139 to reduce the risk of TIM would similarly
reduce the risk of TIA.
TNF-antagonists
Tumor necrosis factor (TNF)-antagonists, mainly infliximab and adalimumab, are the
most  commonly  prescribed  biologicals  in  the  management  of  IBD[34].  Biological
therapy  has  transformed  the  management  of  IBD,  and  has  become  the  largest
contribution to IBD healthcare expenditure[35]. Despite their established efficacy, up to
a third of patients with IBD will have no response at all to these agents (primary non-
response)[36].  An additional  third of  patients  will  eventually  fail  TNF-antagonist
therapy after initial response (loss-of-response)[36]. Small hypothesis-driven studies
into genetic determinants of primary non-response have reported conflicting data or
have been underpowered to identify genetic variants worth translating into clinical
practice[8,37].
Immunogenicity of TNF-antagonists
The formation of anti-drug antibodies, referred to as immunogenicity, is the most
important cause of the loss-of-response and hypersensitivity reactions that often lead
to treatment failure[38].  Although concomitant use of immunosuppressive therapy
reduces immunogenicity, up to 65% of patients treated with infliximab and 38% of
patients treated with adalimumab will eventually develop anti-drug antibodies[38].
Moreover, many patients are still treated with TNF-antagonist monotherapy because
of  adverse  events,  infections  and  possibly  malignancies  associated  with  im-
munosuppressive therapy[39,40]. Recently, the HLA-DQA1*05 haplotype was identified
as a genetic determinant of immunogenicity to TNF-antagonists. Carriership of the
HLA-DQA1*05 haplotype is associated with a 2-fold increased risk of immunogenicity
to TNF-antagonists, regardless of the type of drug used [i.e., infliximab (Remicade,
CT-P13) or adalimumab][41]. Pre-treatment HLA-DQA1*05 genetic testing has not yet
been considered for clinical implementation. TNF-antagonist therapy is a major driver
of IBD healthcare expenditure, and im-munogenicity often leads to therapeutic failure
and  adverse  events.  Pre-treatment  HLA-DQA1*05  genetic  testing  thus  has  the
potential  to  personalize  TNF-antagonist  therapy  and  allow  targeted  use  of
concomitant immunosuppressive therapy to minimize risk and maximize response[41].
From identification to implementation
Patients with IBD need life-long adherence to drugs to maintain disease remission,
improve quality of life and reduce the need for surgery. Although the outcomes of
medical therapies have greatly improved over the last decades, substantial inter-
individual variability remains in terms of both efficacy and toxicity. Many patients
with IBD do not  achieve disease remission,  lose response after  initial  successful
treatment, or develop severe drug-induced adverse events. Indeed, IBD experts will
agree that there is no such thing as “one-size-fits-all“ in the management of IBD.
However,  there  is  still  an  unmet  need  for  patient  stratification  to  guide  this
personalized care.
Several genetic markers have been identified as strong determinants of (adverse)
response to drugs used in the management of IBD. However, the uptake of routine
pre-treatment genetic testing to better stratify patients with IBD has been slow. For
example, the association between TPMT genotypes and severe TIM was established
nearly three decades ago[18]. Although the American Gastroenterological Association
and the British Society of Gastroenterology now recommend routine TPMT testing
(enzymatic activity or genotype) prior to initiating thiopurine therapy, the European
Crohn’s  and  Colitis  Organisation  guidelines  still  do  not[42-44].  Likewise,  TPMT
screening  is  used  in  IBD  clinical  practice  on  a  limited  scale  in  many  European
countries. No other PGx tests are currently implemented in IBD clinical care.
This slow uptake of pre-treatment genetic testing in the management of IBD is a
reflection of the challenges associated with the path from identification of a genetic
marker  to  clinical  implementation.  First,  idiosyncratic  adverse  events  are  often
notoriously difficult to characterize due to the small number of cases available to
individual  researchers.  Recent  efforts  led  by  the  United  Kindom  IBD  Genetics
Consortium  have  successfully  conducted  both  prospective  (e.g.,  PANTS)  and
retrospective (e.g.,  PRED4) PGx studies in the context of IBD management[15,29,41,45]
.However,  additional  large  international  consortia  are  needed  to  facilitate  the
collection of rigorously characterized cohorts of patients who develop (rare) adverse
events.  Stringent  phenotype  definitions  should  be  established  to  prevent
heterogeneity, which significantly reduces the power to find consistent associations[46].
Then, the clinical validity of a PGx test has to be established. Clinical validity refers to
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the performance of the test, such as the discriminative ability and predictive value[47].
Key to this is replication in independent cohorts. Failure to replicate a PGx association
makes it difficult to establish clinical validity estimates. The implementation of a pre-
treatment PGx test into clinical care, however, is generally motivated by more than
the discriminative ability of a test. Clinical utility takes assessment of the test a step
further and focuses on the likelihood that the test concerned will lead to an improved
health outcome[48,49]. Therefore, the clinical utility of a given test is dependent upon
parameters such as whether or not an effective alternative therapy is available and the
relative  risk  of  the  predicted  outcome  (i.e.,  response  or  adverse  event).  The
development of novel therapies, although more expensive, provides alternatives for
patients with IBD genetically at risk for adverse events. This adds to the clinical utility
of  pre-treatment PGx testing in IBD care.  Finally,  the incidence of  the predicted
outcome  and  prevalence  of  the  risk  allele  may  differ  between  different  ethnic
populations,  and both  affect  the  clinical  utility  of  a  given  test  within  a  specific
population. In the context of IBD, for example, the incidence TIM is much higher in
Asian  populations  compared  to  European  populations,  which  can  be  largely
attributed to trans-ethnic differences in TPMT and NUDT15 risk allele frequencies[24].
This renders the clinical utility of PGx tests before the start of thiopurine treatment
higher in Asian populations than in European populations.
Like most diagnostic or therapeutic interventions, clinical implementation of pre-
treatment PGx tests has traditionally demanded a randomized controlled trial (RCT)
to assess its clinical utility and cost-effectiveness. RCTs are, however, very expensive,
require  large  sample  sizes  and often  fail  to  produce  consistent  results.  Primary
outcomes of RCTs are often averaged across the entire population per study arm. This
is,  of  course,  the  exact  opposite  of  personalized  medicine,  where  a  particular
treatment is not chosen based on the “average patient”, but on characteristics of an
individual, for example, a genetic profile. A good example in the context of IBD is a
recently  performed RCT to  determine whether  pre-treatment  TPMT  genotyping
would affect outcomes of patients with IBD[50].  In this study, pre-treatment TPMT
genotyping  did  not  reduce  overall  incidence  of  TIM  in  the  intervention  group.
However, there was a 10-fold reduction in TIM in TPMT variant carriers who received
dose reduction, compared with variant carriers who did not. While 609 patients with
IBD were enrolled in this study, post-hoc analysis showed that 42,556 patients should
have been enrolled to show a reduction in TIM for the entire intervention group. It is
unlikely that there will be much interest from industry and academia to conduct (and
fund) these large clinical trials for drugs already approved. Indeed, decisions to use
PGx tests will probably need to be based on other types of evidence, including case-
control studies, cohort studies and retrospective analyses of data[51].
Greater availability and falling costs of genetic testing means that increasingly the
question is not whether to genotype, but how to best utilize genetic data. Future
studies should focus on the cost-effectiveness of different means of genotyping for
different ethnic populations. Targeted sequencing of NUDT15 and TPMT would cost
approximately $300 per patient, while genome-wide genotyping arrays are available
for less than $40 per patient[52].  Custom genotyping arrays could be designed that
include known pharmacogenetic variants, extensive coverage of areas with a high
likelihood of pharmacogenetic associations and medium coverage of the rest of the
genome. Clinical genetic testing requires accredited pipelines with a genetic assay of
high accuracy, consistent quality of data analysis and interpretation, and a short
overall  turnaround time. These pipelines take genetic data as input,  functionally
annotate the genetic data via curated databases such as PharmGKB, and translate
these data into individual therapeutic recommendations for all well-known gene-drug
pairs, including TPMT and NUDT15[53]. These individual reports are referred to as
pharmacogenetic passports (Figure 1). Once a patient has been genotyped, novel PGx
associations could be automatically added via continuous annotation to curated
databases.  Worldwide,  many PGx implementation  programs have  already been
initiated[54]. The use of a custom genotyping array, in contrast to sequencing, limits
opportunities for the identification of novel PGx associations to a degree, but makes
the required quality control,  quick data interpretation and global  registration of
known PGx associations more easily achievable.
CONCLUSION
We have discussed several clinically useful genetic determinants of response to IBD
drugs. Given the enormous potential it has for the care of patients with IBD, pre-
treatment  genetic  tests  should  be  incorporated  into  clinical  IBD  management
guidelines.  Detailed  thiopurine-dosing  recommendations  based  on  TPMT  and
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Figure 1
Figure 1  Example of an automated computational pipeline that creates an individual pharmacogenetic
passport based on an individual’s genotype. In this case, the individual is a heterozygous carrier of the loss-of-
function TPMT*3A allele and homozygous carrier of the NUDT15*1 allele. Heterozygous carriers of TPMT*3A are at
risk for thiopurine-induced myelosuppression due to intermediate TPMT enzyme activity levels. Hence, a reduced
dose (30%-80% of target dose) is strongly recommended. Patients with a NUDT15*1/*1 genotype are considered as
NUDT15 normal metabolizers[28]. TPMT: Thiopurine S-methyltransferase; NUDT: Nudix hydrolase.
NUDT15 genotypes, provided by CPIC, can be easily adopted. Follow-up studies are
required  to  assess  how  to  translate  genetic  variation  in  HLA  into  therapeutic
recommendations regarding the risk of TIP and ITA, respectively. It is likely that
future pharmacogenetic studies will identify more predictive genetic variants. For
clinical  implementation  of  pre-treatment  genetic  tests,  we  suggest  a  custom
genotyping array that can be easily deployed across centers of secondary care around
the globe and adjusted if more predictive variants are identified.
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